Unit Converter
NT‐proBNP (N-terminal pro B-type natriuretic peptide)
Synonym
B-type natriuretic peptide, N-terminal pro b-type natriuretic peptide, Brain natriuretic peptide, proBNP, N-terminal proBNP
Units of measurement
pmol/L, pg/mL, pg/dL, pg/100mL, pg%, pg/L, ng/L
NT-proBNP (N-terminal pro-B-type Natriuretic Peptide)
(Major Cardiac Biomarker for Heart Failure Diagnosis, Prognosis & Risk Stratification)
Synonyms
- NT-proBNP
- N-terminal pro–BNP
- N-proBNP
- ProBNP (1–76 fragment)
- Inactive BNP fragment
- Natriuretic peptide precursor fragment
Units of Measurement
- pmol/L
- pg/mL
- pg/dL
- pg/100 mL
- pg%
- pg/L
- ng/L
Molecular Weight
~8.5 kDa (76–amino-acid inactive peptide)
Unit Conversions
Mass ↔ Molar
Molecular weight = 8500 g/mol
1 pmol/L=8.5 pg/mL1\ \text{pmol/L} = 8.5\ \text{pg/mL}1 pmol/L=8.5 pg/mL 1 pg/mL=0.1176 pmol/L1\ \text{pg/mL} = 0.1176\ \text{pmol/L}1 pg/mL=0.1176 pmol/L
pg/mL ↔ ng/L
1 pg/mL=1 ng/L1\ \text{pg/mL} = 1\ \text{ng/L}1 pg/mL=1 ng/L
pg/dL
1 pg/mL=100 pg/dL1\ \text{pg/mL} = 100\ \text{pg/dL}1 pg/mL=100 pg/dL
Description
NT-proBNP is the inactive peptide fragment released from cleavage of proBNP into:
- BNP (active hormone, 32 aa)
- NT-proBNP (inactive, 76 aa)
NT-proBNP is:
- More stable in blood
- Has longer half-life (60–120 minutes)
- Less affected by rapid physiologic changes
This makes it a superior biomarker for:
- Heart failure diagnosis
- Risk assessment
- Monitoring treatment
- Prognosis determination
Released in response to:
- Increased myocardial wall stress
- Ventricular stretch
- Pressure or volume overload
Physiological Role
Although inactive, NT-proBNP reflects the activation of the natriuretic peptide system, which promotes:
- Natriuresis
- Vasodilation
- Inhibition of RAAS
- Reduction in cardiac preload & afterload
Clinical Significance
HIGH NT-proBNP
1. Heart Failure (Primary Use)
Elevated in:
- Acute decompensated HF
- Chronic HF
- Left ventricle systolic/diastolic dysfunction
Diagnostic Thresholds (ESC & ACC Guidelines)
Rule-out of HF (Acute):
- NT-proBNP < 300 pg/mL → Acute HF very unlikely
Age-stratified rule-in thresholds (Acute):
- < 50 years → >450 pg/mL
- 50–75 years → >900 pg/mL
- 75 years → >1800 pg/mL
Chronic HF (non-acute):
- >125 pg/mL → strongly suggests HF
2. Other Causes of Elevated NT-proBNP
- Pulmonary embolism
- Pulmonary hypertension
- Atrial fibrillation
- Sepsis
- Renal failure (reduced clearance)
- ACS / myocardial ischemia
- Stroke / subarachnoid hemorrhage
- Severe anemia
- Cirrhosis
- Severe COPD exacerbation
LOW NT-proBNP
Usually excludes HF in symptomatic patients.
Clinical meaning
- NT-proBNP < 300 pg/mL (acute dyspnea) strongly rules out heart failure
- Very low levels in obese patients due to reduced natriuretic peptide secretion
Reference Intervals
(Mayo, ESC 2021, ACC/AHA HF Guidelines)
Normal (General Population)
- < 125 pg/mL (chronic)
- < 300 pg/mL (acute settings)
Age-Adjusted Normal (ESC)
| Age | Normal Upper Limit |
| <50 years | <300 pg/mL |
| 50–75 years | <450 pg/mL |
| >75 years | <900 pg/mL |
Severe HF Indicators
- >5000 pg/mL → high mortality risk
- >10,000 pg/mL → advanced decompensated HF
Units Description
pg/mL / ng/L
Primary reporting unit.
pg/dL / pg/100 mL / pg%
Older clinical units.
pmol/L
Molar unit used in research.
Diagnostic Uses
1. Diagnosis of Heart Failure
Best biomarker for:
- Acute HF in emergency
- Chronic HF in outpatient settings
2. Prognosis
Higher NT-proBNP = poorer survival in:
- HF
- ACS
- Pulmonary hypertension
3. Treatment Monitoring
Levels fall with:
- Diuretics
- ACE inhibitors
- ARNI (sacubitril/valsartan)
- Beta-blockers
4. Differentiating Dyspnea
Helps distinguish:
- HF vs COPD
- HF vs pneumonia
5. Renal Disease
Interpreted cautiously because reduced clearance elevates values.
Analytical Notes
- Sample: plasma (EDTA preferred)
- Stable for hours; more stable than BNP
- Renal dysfunction → falsely elevated
- Obesity → falsely low
- Avoid hemolysis and delays in processing
Clinical Pearls
- NT-proBNP <300 pg/mL rules out acute heart failure better than ECG or chest X-ray.
- Obese patients may have low NT-proBNP despite HF — interpret carefully.
- Serial NT-proBNP measurements reflect treatment response.
- Markedly high levels (>10,000 pg/mL) occur in severe HF and renal failure.
- BNP and NT-proBNP are both valid, but NT-proBNP is more stable.
Interesting Fact
The hormone BNP was originally extracted from porcine brain tissue, which is why it is called “Brain Natriuretic Peptide”—even though the heart produces most of it.
SEO Unit Converter Text
NT-proBNP converter — convert between pmol/L, pg/mL, ng/L, and pg/dL. Includes ESC/ACC diagnostic cutoffs, age-specific thresholds, and HF prognostic interpretation.
References
- Tietz Clinical Chemistry & Molecular Diagnostics, 8th Edition — Cardiac Markers
- ESC 2021 Heart Failure Guidelines
- ACC/AHA Heart Failure Guidelines
- Mayo Clinic Laboratories — NT-proBNP
- ARUP Consult — Natriuretic Peptide Testing
- MedlinePlus / NIH — BNP/NT-proBNP Testing
=====
N-ACETYLOPROCAINAMIDE (NAPA)
(Active Metabolite of Procainamide — Major Therapeutic Drug Monitoring Marker in Cardiac Arrhythmias)
Synonyms
- N-acetylprocainamide
- NAPA
- Acetylprocainamide
- APA
- Procainamide metabolite
Units of Measurement
- µmol/L
- mg/L
- mg/dL
- mg/100 mL
- mg%
- µg/mL
Molecular Weight
264.3 g/mol
Key Unit Conversions
Molar ↔ Mass
1 mg/L=3.78 µmol/L1\ \text{mg/L} = 3.78\ \text{µmol/L}1 mg/L=3.78 µmol/L 1 µmol/L=0.264 mg/L1\ \text{µmol/L} = 0.264\ \text{mg/L}1 µmol/L=0.264 mg/L
mg/dL ↔ mg/L
1 mg/dL=10 mg/L1\ \text{mg/dL} = 10\ \text{mg/L}1 mg/dL=10 mg/L
µg/mL
1 µg/mL=1 mg/L1\ \text{µg/mL} = 1\ \text{mg/L}1 µg/mL=1 mg/L
mg%
\text{mg%} = \text{mg/dL}
Description
N-acetylprocainamide (NAPA) is the major active metabolite of the antiarrhythmic drug procainamide.
Produced via hepatic N-acetylation, NAPA has:
- Class III antiarrhythmic properties
- Longer half-life than procainamide
- Important role in overall therapeutic and toxic effects
Therapeutic drug monitoring (TDM) of both procainamide + NAPA is essential because:
- Each has independent pharmacologic activity
- Total drug effect = procainamide + NAPA
- Renal failure causes NAPA accumulation, increasing toxicity risk
Physiological Role
None — NAPA is a pharmacologic compound, not naturally occurring.
Clinical Significance
Therapeutic Uses
NAPA contributes to management of:
- Ventricular arrhythmias
- Atrial arrhythmias
- Supraventricular tachycardia (SVT)
- Atrial fibrillation conversion in some cases
NAPA is especially important in long-term procainamide therapy.
HIGH NAPA Levels (Toxicity)
Symptoms
- Hypotension
- Bradyarrhythmias
- QRS or QT prolongation
- Torsades de pointes (most feared complication)
- Dizziness, syncope
- CNS effects
- Seizures (rare)
Major Causes
- Renal impairment (primary cause)
- High procainamide dose
- Slow acetylators vs fast acetylators (pharmacogenetic variability)
- Drug interactions (cimetidine, amiodarone)
- Heart failure or shock (reduced clearance)
NAPA increases QT interval more readily than procainamide → higher risk of torsades.
LOW NAPA Levels
Indicate:
- Subtherapeutic dosing
- Poor procainamide metabolism
- Hyperfiltration (rare)
- Very recent dose (before steady state)
- Non-adherence
Reference Intervals (Therapeutic Ranges)
(Tietz 8E + Mayo + ARUP + ACCP TDM)
Therapeutic Range
- 10 – 30 mg/L
(= 10–30 µg/mL)
(= 38 – 113 µmol/L)
Toxic Range
- > 40 mg/L
(= > 40 µg/mL)
(= > 150 µmol/L)
Combined Level Interpretation
(Total antiarrhythmic activity = procainamide + NAPA)
- Combined 10–30 mg/L → desired
- Combined > 30–40 mg/L → caution
- Combined > 40 mg/L → high toxicity risk
Units Description
mg/L
Most common clinical reporting unit.
µg/mL
Equivalent to mg/L.
µmol/L
Preferred in pharmacokinetic studies.
mg/dL / mg%
Older units used in older pharmacology literature.
Diagnostic Uses
1. Therapeutic Drug Monitoring (Primary Use)
Used to adjust procainamide therapy.
2. Evaluate Suspected Toxicity
- QT prolongation
- Arrhythmias
- Hypotension
- Wide QRS complex
3. Monitor Renal Failure Patients
NAPA clearance is almost entirely renal → accumulation is common.
4. Optimize Antiarrhythmic Therapy
Maintaining combined levels within therapeutic range reduces:
- Recurrence of arrhythmias
- Drug-induced proarrhythmia
- Mortality in acute arrhythmia management
Analytical Notes
- Sample: serum or plasma
- Trough level preferred (just before next dose)
- LC–MS/MS or immunoassay used
- Hemolysis & lipemia interfere with chromatographic assays
- Levels shift significantly with acute renal changes
- Measure both procainamide + NAPA simultaneously
Clinical Pearls
- NAPA is more pro-arrhythmic (QT-prolonging) than procainamide.
- In renal failure, NAPA accumulates rapidly — monitor closely.
- Fast/slow acetylators (genetics) alter procainamide → NAPA ratio.
- Therapeutic effect depends on combined drug levels, not either alone.
- If QTc > 500 ms → suspect NAPA toxicity.
- For torsades, discontinue drug + give IV magnesium.
Interesting Fact
NAPA is structurally similar to procainamide but has longer half-life, giving it more stable plasma concentrations — which is why total drug monitoring must include both molecules.
SEO Unit Converter Text
N-acetylprocainamide converter — convert between µmol/L, mg/L, mg/dL, mg%, and µg/mL. Includes therapeutic/toxic ranges, renal adjustment notes, and combined procainamide–NAPA interpretation.
References
- Tietz Clinical Chemistry & Molecular Diagnostics, 8th Edition — Therapeutic Drug Monitoring
- ACCP Guidelines on Therapeutic Drug Monitoring
- Mayo Clinic Laboratories — NAPA
- ARUP Consult — Antiarrhythmic Drug TDM
- MedlinePlus / NIH — Procainamide & Metabolites